Eli Lilly and Company (LLY) Projected to Post Earnings on Thursday

Eli Lilly and Company (NYSE:LLY) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $5.56 per share and revenue of $14.40 billion for the quarter.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business’s revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.58 EPS. On average, analysts expect Eli Lilly and Company to post $23 EPS for the current fiscal year and $31 EPS for the next fiscal year.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $759.76 on Thursday. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market cap of $720.05 billion, a PE ratio of 61.82, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40. The stock has a 50-day moving average price of $774.07 and a 200-day moving average price of $800.13.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. UBS Group cut their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,012.56.

Hedge Funds Weigh In On Eli Lilly and Company

An institutional investor recently raised its position in Eli Lilly and Company stock. Revolve Wealth Partners LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,471 shares of the company’s stock after acquiring an additional 40 shares during the period. Revolve Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $1,136,000 at the end of the most recent reporting period. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.